Background: EZH2 is ubiquitously expressed during early embryo genesis, and becomes restricted to the central and peripheral nervous systems and sites of fetal hematopoiesis during later development. EZH2 is involved in the progression of prostate cancer and is also a marker that distinguishes prostate cancers at risk of lethal progression from indolent prostate cancer. KMT6/Enhancer of zeste homologue 2 (EZH2) is a histone lysine methyl transferase which is associated with transcriptional repression. It is a component of the polycomb repressive complexes PRC2 and PRC3. The HMTase activity of EZH2 is carried out by the SET domain. The PRC2 complex catalyses histone H3 K27 trimethylation, of which KMT6 / EZH2 is the catalytic subunit.
Description: Rabbit polyclonal to EZH2
Immunogen: KLH conjugated synthetic peptide derived from EZH2
Specificity: ·Reacts with Human, Mouse and Rat.
·Isotype: IgG
Application: ·Western blotting: 1/100-500. Predicted Mol wt: 85 kDa;
·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;
·Immunocytochemistry/Immunofluorescence: 1/100;
·Immunoprecipitation: 1/50;
·ELISA: 1/500;
·Optimal working dilutions must be determined by the end user.
